Ann: Company Presentation - Investor Insights, page-8

Includes testimony from Dr David Speakman
In Q&A at the end of this recent webinar. Min 11 Answers the competitor Q.

Just a few notes.
Gross margin around 70% and improve at volumes and scale.
There are no competitors in lipids space,
However there are genetic tests which tell you what you could occur, but their test tells you what is occurring.
There are two out there from pana cancer tests from Grail and Exact Sciences / two companies Korea / Canada but not launched with clinics.
IP covers both lipid signature for breast test, and use of lipids for other cancer detection. Next Lung cancer.
Incredible growth market for those who get mams, and those who dont, and all age groups. A breast test for all women is their mantra.
US just changed their guidelines for screening testing from 40-75 y/o to annually, not every two years.